News

July 20, 2022

Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-based platform

Auron expands its leadership team with the appointments of David Millan, Ph.D., as Chief Scientific Officer, Thomas Graeber, Ph.D., as Chief Data Officer, Andrea Armstrong as Chief People Officer and Briggs Morrison, M.D., as Independent Chairman of the Board. Newton, Mass., July 20, 2022 — Auron Therapeutics (“Auron”), a biopharmaceutical company focused on developing therapies…